The Cutting Edge of Medical Technology Content, Community & Collaboration
J&J Describes Emerging Corporate Philosophy on Open Innovation & Collaboration
Colleagues,
As reported in Genome Web BioTech Transfer Week ... "collaboration" was the watch word at the Biotechnology Industry Organization annual meeting in Atlanta, as many large pharmas and biotechs shared their new strategy of partnering and openness ..
... Johnson & Johnson, for example, through its Corporate Office of Science and Technology, or COSAT, has committed $750,000 over five years to the Massachusetts Institute of Technology's Deshpande Center for Technological Innovation; and continues to provide undisclosed funding to research projects under the Maryland Technology Development Corporation, or TEDCO.
... Other notable examples include alliances by the Salk Institute with Ipsen and Sanofi-Aventis; partnerships between Vanderbilt University and Janssen Pharmaceuticals, and Northwestern University and Baxter; and pacts between the University of California, San Francisco and Pfizer, and GlaxoSmithKline and the Immune Disease Institute.
In a recent interview, Garry Neil, Corporate vice president, Corporate Office of Science and Technology, Johnson & Johnson, noted that open innovation & collaboration "is a natural evolution of our strategy rather than being a brand new strategy. For a long time we've prided ourselves at being one of the premier partnering companies in the biomedical industry, including partnerships with academic institutions, small companies, and large companies, as well as public-private consortia."
He added that "... like others, there is no question that our activities in this area have ramped up, and we're devoting more resources and time to it. We also have higher expectations for return on our investments in this space...We feel that there is an enormous amount of innovation at universities, research institutes, [and] small companies that we need to take advantage of...We seek external partnerships both to source new product and business opportunities, [and] to find new technologies and models to enhance our internal capabilities."
"...we don't believe that the best use of money with the university partner is to just dump a big grant on them and see what comes out of it. We prefer what we call "co-managed funds," where both we [and] the university put money in, generating a grant pool to which investigators at the university can apply. Then we work together to select specific projects."
"...to the specific point, if we're looking at medical devices, we want to see something with enough data to give us a reason to believe this really could be an interesting and unique product. And then we try to construct a milestone-driven program with the investigator where we can lay out what it would look like to get them to a working prototype, where we're starting to generate a little bit of data."
"... Increasingly we like to set up a master service agreement at a corporate level with universities that will enable us to bring in more focused proposals more easily and reduce the bureaucracy."
"... right now, I can say with certainty that we're very interested in regenerative medicine, neurostimulation, oncology, diabetes and metabolic disease."
Read on at: http://www.genomeweb.com/biotechtransferweek/qa-head-jjs-cosat-rent...
ENJOY!
CC
As reported in Genome Web BioTech Transfer Week ... "collaboration" was the watch word at the Biotechnology Industry Organization annual meeting in Atlanta, as many large pharmas and biotechs shared their new strategy of partnering and openness ..
... Johnson & Johnson, for example, through its Corporate Office of Science and Technology, or COSAT, has committed $750,000 over five years to the Massachusetts Institute of Technology's Deshpande Center for Technological Innovation; and continues to provide undisclosed funding to research projects under the Maryland Technology Development Corporation, or TEDCO.
... Other notable examples include alliances by the Salk Institute with Ipsen and Sanofi-Aventis; partnerships between Vanderbilt University and Janssen Pharmaceuticals, and Northwestern University and Baxter; and pacts between the University of California, San Francisco and Pfizer, and GlaxoSmithKline and the Immune Disease Institute.
In a recent interview, Garry Neil, Corporate vice president, Corporate Office of Science and Technology, Johnson & Johnson, noted that open innovation & collaboration "is a natural evolution of our strategy rather than being a brand new strategy. For a long time we've prided ourselves at being one of the premier partnering companies in the biomedical industry, including partnerships with academic institutions, small companies, and large companies, as well as public-private consortia."
He added that "... like others, there is no question that our activities in this area have ramped up, and we're devoting more resources and time to it. We also have higher expectations for return on our investments in this space...We feel that there is an enormous amount of innovation at universities, research institutes, [and] small companies that we need to take advantage of...We seek external partnerships both to source new product and business opportunities, [and] to find new technologies and models to enhance our internal capabilities."
"...we don't believe that the best use of money with the university partner is to just dump a big grant on them and see what comes out of it. We prefer what we call "co-managed funds," where both we [and] the university put money in, generating a grant pool to which investigators at the university can apply. Then we work together to select specific projects."
"...to the specific point, if we're looking at medical devices, we want to see something with enough data to give us a reason to believe this really could be an interesting and unique product. And then we try to construct a milestone-driven program with the investigator where we can lay out what it would look like to get them to a working prototype, where we're starting to generate a little bit of data."
"... Increasingly we like to set up a master service agreement at a corporate level with universities that will enable us to bring in more focused proposals more easily and reduce the bureaucracy."
"... right now, I can say with certainty that we're very interested in regenerative medicine, neurostimulation, oncology, diabetes and metabolic disease."
Read on at: http://www.genomeweb.com/biotechtransferweek/qa-head-jjs-cosat-rent...
ENJOY!
CC
Views: 9
MedTechIQ VideoLibrary
Upcoming Events
© 2025 Created by CC-Conrad Clyburn-MedForeSight.
Powered by
